cryoport inc - CYRX

CYRX

Close Chg Chg %
15.47 -0.33 -2.13%

Pre-Market

15.14

-0.33 (2.13%)

Volume: 531.88K

Last Updated:

Sep 9, 2026, 4:00 PM EDT

Company Overview: cryoport inc - CYRX

CYRX Key Data

Open

$15.56

Day Range

15.08 - 15.62

52 Week Range

7.61 - 17.20

Market Cap

$800.76M

Shares Outstanding

50.65M

Public Float

48.43M

Beta

1.90

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.82

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

516.24K

 

CYRX Performance

1 Week
 
-4.24%
 
1 Month
 
-0.72%
 
3 Months
 
3.56%
 
1 Year
 
75.23%
 
5 Years
 
-76.79%
 

CYRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About cryoport inc - CYRX

Cryoport, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

CYRX At a Glance

Cryoport, Inc.
112 Westwood Place
Brentwood, Tennessee 37027
Phone 1-949-470-2300 Revenue 176.18M
Industry Air Freight/Couriers Net Income -38,652,000.00
Sector Transportation Employees 738
Fiscal Year-end 12 / 2026
View SEC Filings

CYRX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.728
Price to Book Ratio 1.04
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -20.404
Enterprise Value to Sales 1.944
Total Debt to Enterprise Value 0.674

CYRX Efficiency

Revenue/Employee 238,722.222
Income Per Employee -52,373.984
Receivables Turnover 5.281
Total Asset Turnover 0.24

CYRX Liquidity

Current Ratio 2.174
Quick Ratio 2.068
Cash Ratio 1.878

CYRX Profitability

Gross Margin 39.96
Operating Margin -23.804
Pretax Margin -18.26
Net Margin -21.939
Return on Assets -4.626
Return on Equity -7.511
Return on Total Capital -4.632
Return on Invested Capital -5.778

CYRX Capital Structure

Total Debt to Total Equity 45.901
Total Debt to Total Capital 31.461
Total Debt to Total Assets 30.16
Long-Term Debt to Equity 8.886
Long-Term Debt to Total Capital 5.578
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cryoport Inc - CYRX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
237.28M 233.25M 228.38M 176.18M
Sales Growth
+6.59% -1.70% -2.09% -22.86%
Cost of Goods Sold (COGS) incl D&A
148.47M 150.21M 145.91M 105.78M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
22.77M 27.49M 30.76M 25.15M
Depreciation
7.70M 11.20M 13.60M 12.50M
Amortization of Intangibles
15.06M 16.29M 17.16M 12.65M
COGS Growth
+5.69% +1.17% -2.86% -27.51%
Gross Income
88.81M 83.05M 82.47M 70.40M
Gross Income Growth
+8.13% -6.49% -0.69% -14.64%
Gross Profit Margin
+37.43% +35.60% +36.11% +39.96%
2022 2023 2024 2025 5-year trend
SG&A Expense
118.55M 141.69M 150.48M 112.34M
Research & Development
15.72M 18.04M 17.71M 17.04M
Other SG&A
102.83M 123.65M 132.77M 95.30M
SGA Growth
+24.06% +19.52% +6.20% -25.35%
Other Operating Expense
- - - -
-
Unusual Expense
13.57M 49.53M 45.26M (6.64M)
EBIT after Unusual Expense
(43.31M) (108.17M) (113.26M) (35.30M)
Non Operating Income/Expense
14.36M 14.32M 3.89M 5.49M
Non-Operating Interest Income
8.47M 10.58M 9.89M 9.80M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
6.14M 5.50M 4.11M 2.36M
Interest Expense Growth
+30.99% -10.40% -25.35% -42.53%
Gross Interest Expense
6.14M 5.50M 4.11M 2.36M
Interest Capitalized
- - - -
-
Pretax Income
(35.09M) (99.35M) (113.48M) (32.17M)
Pretax Income Growth
+87.18% -183.09% -14.22% +71.65%
Pretax Margin
-14.79% -42.59% -49.69% -18.26%
Income Tax
2.24M 239.00K 1.28M 1.80M
Income Tax - Current - Domestic
70.00K 73.00K 59.00K 79.00K
Income Tax - Current - Foreign
2.63M 2.26M 1.66M 1.47M
Income Tax - Deferred - Domestic
1.08M (701.00K) (326.00K) 182.00K
Income Tax - Deferred - Foreign
(1.54M) (1.40M) (120.00K) 68.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(37.33M) (99.59M) (114.76M) (33.97M)
Minority Interest Expense
- - - -
-
Net Income
(37.33M) (99.59M) (114.76M) (33.97M)
Net Income Growth
+86.45% -166.75% -15.23% +70.40%
Net Margin Growth
-15.73% -42.69% -50.25% -19.28%
Extraordinaries & Discontinued Operations
- - - (4.68M)
-
Discontinued Operations
- - - (4.68M)
-
Net Income After Extraordinaries
(37.33M) (99.59M) (114.76M) (38.65M)
Preferred Dividends
8.00M 8.00M 8.00M 8.00M
Net Income Available to Common
(45.33M) (107.59M) (122.76M) (46.65M)
EPS (Basic)
-0.9254 -2.2075 -2.4875 -0.9317
EPS (Basic) Growth
+85.02% -138.55% -12.68% +62.54%
Basic Shares Outstanding
48.99M 48.74M 49.35M 50.07M
EPS (Diluted)
-0.9254 -2.2075 -2.4875 -0.9317
EPS (Diluted) Growth
+85.02% -138.55% -12.68% +62.54%
Diluted Shares Outstanding
48.99M 48.74M 49.35M 50.07M
EBITDA
(6.97M) (31.16M) (37.25M) (16.79M)
EBITDA Growth
-202.20% -346.75% -19.55% +54.94%
EBITDA Margin
-2.94% -13.36% -16.31% -9.53%

Snapshot

Average Recommendation BUY Average Target Price 19.333
Number of Ratings 9 Current Quarters Estimate -0.177
FY Report Date 09 / 2026 Current Year's Estimate -0.788
Last Quarter’s Earnings -0.20 Median PE on CY Estimate N/A
Year Ago Earnings 1.40 Next Fiscal Year Estimate -0.644
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 9 9
Mean Estimate -0.18 -0.17 -0.79 -0.64
High Estimates -0.10 -0.07 -0.54 -0.32
Low Estimate -0.22 -0.21 -0.88 -0.83
Coefficient of Variance -19.61 -24.71 -12.82 -24.91

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cryoport Inc - CYRX

Date Name Shares Transaction Value
Jun 10, 2026 Linda Baddour Director 68,099 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 10, 2026 Linda Baddour Director 16,077 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cryoport Inc in the News